Previous 10 | Next 10 |
ViewRay Announces Closing of Public Offering of Common Stock PR Newswire CLEVELAND , Nov. 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer ...
ViewRay (NASDAQ:VRAY) has priced its public offering of 12.5M common shares at $5.60/share, for gross proceeds of $70M. Underwriters' over-allotment is an additional 1.875M shares. Net proceeds will be used for general corporate purposes, including working capital, and continued R&D and c...
ViewRay (NASDAQ:VRAY) has lost ~9.2% in the post-market after the company announced an underwritten public offering of its common stock. A 30-day option allowing underwriters to purchase an additional 15% of the shares of the common stock is also under consideration. Piper Sandler a...
ViewRay, Inc. (VRAY) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Cassie Mahar - Controller Scott Drake - President and Chief Executive Officer Zach Stassen - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Anthony Petrone...
Image source: The Motley Fool. ViewRay, Inc. (NASDAQ: VRAY) Q3 2021 Earnings Call Nov 04, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: ViewRay, Inc. (VRAY) Q3 2021 Earnings Call Transcript
ViewRay (NASDAQ:VRAY): Q3 GAAP EPS of -$0.15 beats by $0.01. Revenue of $19.18M (+90.1% Y/Y) beats by $2.13M. Shares +0.53%. Press Release For further details see: ViewRay EPS beats by $0.01, beats on revenue
ViewRay Reports Third Quarter 2021 Results PR Newswire CLEVELAND , Nov. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2021. Third Quarter 2021 Highl...
ViewRay Inc. (NASDAQ:VRAY) traded today at a new 52-week high of $7.64. Approximately 202,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares. ViewRay Inc. has overhead space with shares priced $7.54, or 0.1% below the average consensus analys...
Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...
New Outcomes Data Demonstrating Prolonged Survival for Inoperable Pancreatic Cancer Patients Presented at Leading Radiation Oncology Meeting Findings Show Median Overall Survival Of 26 Months for Patients Receiving Ablative Doses with MRIdian MRI-Guided Radiation Therapy PR ...
News, Short Squeeze, Breakout and More Instantly...
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets PR Newswire DENVER , July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (Nasdaq: VRAY) announced today that on July 17 , i...